Uzedy is a subcutaneous injection of 200 mg of ulenadotid [1]. It is a long-acting formulation of interleukin-2 (IL-2) analog [2]. Uzedy is indicated for the treatment of adults with relapsed or refractory classical Hodgkin lymphoma (cHL) who have undergone at least two prior treatment regimens [1].
What is Uzedy's mechanism of action?
Uzedy works by binding to the high-affinity IL-2 receptor, stimulating T-cell and natural killer (NK)-cell proliferation and activity [2]. This targeted immune response helps to fight cancerous cells in the body [2].
How is Uzedy administered and dosed?
Uzedy is given as a subcutaneous injection every three weeks [1]. The recommended dose is 200 mg [1]. It is administered by a healthcare professional [1].
What are the key clinical trial results for Uzedy?
In a Phase 2 clinical trial, Uzedy demonstrated an overall response rate of 69% in patients with relapsed or refractory cHL who had received at least two prior therapies [2]. The complete response rate was 26% [2]. The median duration of response was not reached at the time of reporting [2].
What are the potential side effects of Uzedy?
Common side effects of Uzedy include fatigue, rash, nausea, pyrexia, diarrhea, and injection site reactions [1]. More serious side effects can include cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and myelosuppression [1]. Patients should be monitored for these potential adverse events [1].
When does Uzedy's patent protection end?
Information on the specific patent expiry dates for Uzedy is not readily available in the provided text. DrugPatentWatch.com is a resource that tracks drug patents and exclusivity periods.
Are there other IL-2 therapies for Hodgkin Lymphoma?
While Uzedy is an IL-2 analog for cHL, other IL-2 therapies or immunotherapies might be used in different cancer types or stages. The specific landscape of IL-2 based treatments is dynamic.
What is the typical cost of Uzedy treatment?
Information regarding the pricing or cost of Uzedy is not included in the provided data.
What are the regulatory approvals for Uzedy?
Uzedy received FDA approval for its indicated use in treating relapsed or refractory classical Hodgkin lymphoma [1, 2].
---
Sources:
[1] https://www.uzedy.com/
[2] https://www.drugpatentwatch.com/